Mycobacterium Smegmatis Patents (Class 435/866)
  • Patent number: 7740867
    Abstract: Disclosed are methods for the determination of virulence determinants in bacteria and in particular bacteria of the genus Mycobacterium. Also disclosed are compositions and methods for stimulating an immune response in an animal using bacteria and virulence determinants identified by the methods of the present invention.
    Type: Grant
    Filed: November 27, 2007
    Date of Patent: June 22, 2010
    Assignee: Board of Regents of the University of Nebraska
    Inventors: Raul G. Barletta, N. Beth Harris
  • Patent number: 7094403
    Abstract: The invention relates to Mycobacterium tuberculosis superoxide dismutase antibodies, methods of using them for detection of M. tuberculosis, methods of testing for an inhibitor of an M. tuberculosis superoxide dismutase, and methods of detecting tuberculosis infection.
    Type: Grant
    Filed: January 17, 2003
    Date of Patent: August 22, 2006
    Assignee: Yung Shin Pharmaceutical Ind. Co., Ltd.
    Inventors: Fang-Jen S. Lee, Chung-Hsiun H. Wu
  • Patent number: 6833135
    Abstract: The present invention discloses a DNA fragment that can direct the insertion of heterologous DNA into a specific site (tRNAAla gene) of Mycobacterium spp. genome. This DNA fragment includes the attachment site region (attP) and the integrase gene of the mycobacteriophage Ms6. Heterologous DNA linked to this DNA fragment can be carried into the mycobacterial genome through a site-specific integration mechanism. A new DNA integration process is disclosed that consists in providing the integrase gene on a suicide vector, that transiently produces the integrase required for the insertion of the gene or genes linked to the Ms6 attP region contained in a separated plasmid vector. This process allows the construction of highly stable recombinant mycobacteria which may be used as vaccines and/or therapeutic vehicles.
    Type: Grant
    Filed: June 3, 1999
    Date of Patent: December 21, 2004
    Assignee: Laboratorio Medinfar Produtos Farmaceuticos, LDA.
    Inventors: Jose A. Frazao Moniz Pereira, Alcino Freitas Vieira, Elsa M. Ribeiro Dos Santos-Anes, Miguel A. Da Costa Garcia, Paulo J. Da Silva Alves
  • Patent number: 6821769
    Abstract: This invention relates to the identification, cloning, sequencing and characterization of the iniB, iniA and iniC genes of mycobacteria which are induced by a broad class of antibiotics that act by inhibiting cell wall biosynthesis, including the first line antituberculosis agents, isoniazid and ethambutol. The present invention provides purified and isolated iniB, iniA, iniC and iniB promoter nucleic acids which may comprise the iniBAC operon, as well as mutated forms of these nucleic acids. The present invention also provides one or more single-stranded nucleic acid probes which specifically hybridize to the iniB, iniA, iniC and iniB promoter nucleic acids, and mixtures thereof, which may be formulated in kits, and used in the diagnosis of drug-resistant mycobacterial strain. The present invention also provides methods for the screening and identification of drugs effective against Mycobacterium tuberculosis using induction of the iniB promoter.
    Type: Grant
    Filed: July 31, 2001
    Date of Patent: November 23, 2004
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: David Alland, Barry R. Bloom, William R. Jacobs, Jr.
  • Patent number: 6752994
    Abstract: A mutated mycobacterium selected from the class consisting of mutated M. bovis-BCG, mutated M. tuberculosis, and mutated M. leprae. The mutation of M. bovis-BCG, M. tuberculosis, or M. leprae is preferably effected through an insertional mutation of a mycobacterial gene. The insertional mutagenesis may be effected, for example, through illegitimate recombination or by a mycobacterial transposon. Such mutated mycobacteria may then be transformed with an expression vector(s) containing a complement gene to the gene which is mutated, and preferably also including a heterologous gene.
    Type: Grant
    Filed: July 3, 2001
    Date of Patent: June 22, 2004
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: William R. Jacobs, Jr., Barry Bloom, Ganjam V. Kalpana, Jeffrey D. Cirillo, Ruth McAdam
  • Patent number: 6566121
    Abstract: A mutated mycobacterium selected from the class consisting of mutated M.bovis-BCG, mutated M.tuberculosis, and mutated M. leprae. The mutation of M.bovis-BCG, M.tuberculosis, or M. leprae is preferably effected through an insertional mutation of a mycobacterial gene. The insertional mutagenesis may be effected, for example, through illegitimate recombination or by a mycobacterial transposon. Such mutated mycobacteria may then be transformed with an expression vector(s) containing a complement gene to the gene which is mutated, and preferably also including a heterologous gene.
    Type: Grant
    Filed: May 5, 1997
    Date of Patent: May 20, 2003
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: William R. Jacobs, Jr., Barry Bloom, Ganjam V. Kalpana, Jeffrey D. Cirillo, Ruth McAdam
  • Patent number: 6517845
    Abstract: The invention relates to Mycobacterium tuberculosis superoxide dismutase antibodies, methods of using them for detection of M. tuberculosis, methods of testing for an inhibitor of an M. tuberculosis superoxide dismutase, and methods of detecting tuberculosis infection.
    Type: Grant
    Filed: November 12, 1999
    Date of Patent: February 11, 2003
    Assignee: Yung Shin Pharmaceutical Ind. Co., Ltd.
    Inventors: Fang-Jen S. Lee, Chung-Hsiun H. Wu
  • Patent number: 6403100
    Abstract: This invention provides for novel attenuated strains of Mycobacterium tuberculosis and M. bovis. Attenuation is achieved by eliminating or by downregulating the expression of the &agr;-crystallin heat shock protein gene (“acr gene”). The invention provides for vaccines and methods of vaccinating mammals for protection against Mycobacterium sp. that cause tuberculosis.
    Type: Grant
    Filed: June 27, 2000
    Date of Patent: June 11, 2002
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Clifton E. Barry, III, Ying Yuan, Deborah D. Crane
  • Patent number: 6268201
    Abstract: This invention relates to the identification, cloning, sequencing and characterization of the iniB, iniA and iniC genes of mycobacteria which are induced by a broad class of antibiotics that act by inhibiting cell wall biosynthesis, including the first line antituberculosis agents, isoniazid and ethambutol. The present invention provides purified and isolated iniB, iniA, iniC and iniB promoter nucleic acids which may comprise the iniBAC operon, as well as mutated forms of these nucleic acids. The present invention also provides one or more single-stranded nucleic acid probes which specifically hybridize to the iniB, iniA, iniC and iniB promoter nucleic acids, and mixtures thereof, which may be formulated in kits, and used in the diagnosis of drug-resistant mycobacterial strain. The present invention also provides methods for the screening and identification of drugs effective against Mycobacterium tuberculosis using induction of the iniB promoter.
    Type: Grant
    Filed: October 23, 1998
    Date of Patent: July 31, 2001
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: David Alland, Barry R. Bloom, William R. Jacobs, Jr.
  • Patent number: 6229001
    Abstract: The invention relates to the nucleic acid sequence and amino acid sequence of dihydrofolate reductase (DHFR) from mycobacteria and to expression of recombinant DHFR protein. Utilizing the recombinant protein, novel therapies and diagnostic strategies can be developed and selective antimycobacterial compositions can be designed and utilized to treat mycobacterial infections in patients. This invention includes all or portions of novel recombinant nucleic acids encoding DHFR for mycobacteria such as M. avium, to novel recombinant DHFR peptides produced by such sequences, and to vaccines, diagnostic kits, cells and therapies utilizing these peptides and nucleic acid sequences. The present invention relates to methods for using the sequences of the present invention to develop drugs specific to M. avium and other mycobacteria, to identify and sequence corresponding sequences in species other than M. avium, as well as diagnostic and treatment methods incorporating the disclosed sequences and peptides.
    Type: Grant
    Filed: December 15, 1997
    Date of Patent: May 8, 2001
    Assignee: Southern Research Institute
    Inventors: William W. Barrow, Sabrina Z. Van Ginkel, Thomas P. Dooley, William J. Suling
  • Patent number: 6004771
    Abstract: A method for the preparation of Mycobacteria from any liquid, semi solid or exotic source is described. The extracted Mycobacterial sample is suitable for detection by culture and amplification.
    Type: Grant
    Filed: August 11, 1997
    Date of Patent: December 21, 1999
    Assignee: Integrated Research Technology, LLC
    Inventor: Charles G. Thornton
  • Patent number: 5994346
    Abstract: Exochelins can be used to prevent damage to organs for transplant from the formation or presence of the .circle-solid.OH radical. In particular, the invention is directed to the administration of exochelins to the organ prior to or coincidental with removal from a donor, storage, implantation in a recipient or in conjunction with reestablishment of flow of body fluids to the organ.
    Type: Grant
    Filed: October 30, 1997
    Date of Patent: November 30, 1999
    Assignee: Regents of the University of California
    Inventors: Marcus A. Horwitz, Lawrence D. Horwitz
  • Patent number: 5985596
    Abstract: The present invention relates to a method for enhancing the time of response of an assay for a first bacterium, wherein: a) the first bacterium is exposed to infection by phage particles to which the first bacterium is permissive; b) the infected bacterium is treated to inactivate exogenous phage particles; c) the treated bacterium is cultivated in the presence of a second bacterium which is permissive to infection by the phage or its replicand and which has a doubling rate greater than the effective doubling rate of the first bacterium; and d) assessing the extent of plaque formation and/or of second bacterium growth in the cultivated second bacterium cells.
    Type: Grant
    Filed: July 27, 1998
    Date of Patent: November 16, 1999
    Assignee: Biotec Laboratories Limited
    Inventor: Stuart Mark Wilson
  • Patent number: 5837677
    Abstract: The invention is directed toward the use of desferri-Exochelins to destroy cancer cells or retard or eliminate the growth of those cancer cells.
    Type: Grant
    Filed: June 25, 1997
    Date of Patent: November 17, 1998
    Assignee: Keystone Biomedical, Inc.
    Inventors: Lawrence D. Horwitz, Kathryn B. Horwitz
  • Patent number: 5837480
    Abstract: This invention relates to InhA enzyme crystals and to methods of growing said crystals. This invention is further directed to the utilization of said crystals to determine the three dimensional structure of InhA enzyme utilizing heavy atom derivatives of said crystals, and to the identification and development of compounds which inhibit the biochemical activity of InhA enzyme in bacteria and plants.
    Type: Grant
    Filed: August 21, 1996
    Date of Patent: November 17, 1998
    Assignee: Albert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva University
    Inventors: James Sacchettini, John Blanchard, William R. Jacobs, Jr.
  • Patent number: 5830475
    Abstract: The present invention relates to recombinant mycobacteria, particularly recombinant M. bovis BCG, which express heterologous DNA encoding a product (protein or polypeptide) of interest, such a protein or polypeptide (e.g., an antigen) against which an immune response is desired, or a cytokine.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: November 3, 1998
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Anna Aldovini, Richard A. Young
  • Patent number: 5721209
    Abstract: Exochelins can be used to prevent damage to living tissue from the formation or presence of the (.cndot.OH) radical. In particular, the invention is directed to the administration of exochelins to infarcted myocardium prior to or coincidental with reperfusion to prevent damage to myocardium from iron mediated free radical formation. Also presented is the chemical structure of exochelins and modified exochelins as well as other applications of these materials in the treatment and diagnosis of disease in mammals.
    Type: Grant
    Filed: February 3, 1995
    Date of Patent: February 24, 1998
    Assignee: The Regents of the University of California
    Inventors: Lawrence D. Horwitz, Marcus A. Horwitz, Bradford W. Gibson, Joseph Reeve
  • Patent number: 5658749
    Abstract: A method for the preparation of Mycobacteria from any liquid, semi-solid or exotic source is described. The extracted Mycobacterial sample is suitable for detection by culture and amplification.
    Type: Grant
    Filed: February 23, 1995
    Date of Patent: August 19, 1997
    Assignee: Corning Clinical Laboratories, Inc.
    Inventor: Charles G. Thornton
  • Patent number: 5523214
    Abstract: A method of visually demonstrating the growth of such microorganisms as fungi, yeasts, and bacteria, especially mycobacteria, identifying them, and testing them for sensitivity to antibiotics by the color change of a specific redox indicator system. A mixture of the redox indicators Methylene Blue and resazurin is added to the culture medium. Iron(III) salts mixed with K.sub.3 Fe(CN).sub.6, Iron(II) salts mixed with K.sub.4 Fe(CN).sub.6, or sodium tungstate (Na.sub.2 WO.sub.4) is added to the culture medium.
    Type: Grant
    Filed: May 9, 1994
    Date of Patent: June 4, 1996
    Assignee: Biotest Aktiengesellschaft
    Inventor: Jurgen Horn
  • Patent number: 4777130
    Abstract: A 60-like antigens isolated in a one-step reaction from the bacterial cytoplasma of Mycobacteria are useful for the production of diagnostic tests.
    Type: Grant
    Filed: December 5, 1984
    Date of Patent: October 11, 1988
    Assignee: Andra Biologicals
    Inventor: Roland F. Maes